May 26, 2020 -- Merck and IAVI, a nonprofit scientific research organization, announced that they are partnering to develop a recombinant vesicular stomatitis virus (rVSV) vaccine candidate against SARS-CoV-2.
The vaccine will be developed on the basis of Merck's Ebola Zaire virus vaccine and funding will in part be supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA). Work on the rVSV vaccine candidate is being conducted at IAVI's Vaccine Design and Development Laboratory in Brooklyn, NY.
Under the agreement, IAVI and Merck will work together to advance the development and clinical evaluation of the SARS-CoV-2 vaccine candidate engineered by IAVI scientists. Preclinical development and clinical studies are planned to begin later in 2020 led by Merck.